Effect of heterozygous PPARγ deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 3 47-3, 2003, Pages

  Miles, Philip D G ^a,f   Barak, Yaacov ^e   Evans, Ronald M ^e   Olefsky, Jerrold M ^b,c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d Whittier Institute for Diabetes   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f UCSD MEDICAL CENTER   (United States)

Author keywords

Aging; High fat diet; Insulin resistance; Mice; Peroxisome proliferator activated receptor deficiency; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; CELL RECEPTOR; CHROMAN DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ADIPOCYTE; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HYPERTROPHY; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WILD TYPE; AGING; ANIMAL; C57BL MOUSE; FAT INTAKE; GENETICS; HETEROZYGOTE; INBORN ERROR OF METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; CHROMANS; DIETARY FATS; HETEROZYGOTE; INSULIN RESISTANCE; METABOLISM, INBORN ERRORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037364560     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00312.2002     Document Type: Article

References (31)

1. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, and Evans RM. PPARγ is required for placental, cardiac and adipose tissue development. Mol Cell 4: 585-595, 1999.
2. Carvalho CR, Brenelli SL, Silva AC, Nunes AL, Velloso LA, and Saad MJ. Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 137: 151-159, 1996.
3. Fink R, Wallace P, and Olefsky JM. Effects of aging on glucose-mediated glucose disposal and glucose transport. J Clin Invest 77: 2034-2041, 1986.
4. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, and Horikoshi H. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure in C57BL/KsJ-db/db mice. Metabolism 40: 1213-1218, 1991.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, and Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558, 1988.
6. Hirsch J and Gallian E. Methods for the determination of adipose cell size in man and animals. J Lipid Res 9: 110-119, 1968.
7. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, and Shiraishi I. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14: 1083-1086, 1991.
8. Kamohara S, Burcelin R, Halaas JL, Friedman JM, and Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389: 374-377, 1997.
9. Khoursheed M, Miles PDG, Gao K-M, Lee M-K, Moossa AR, and Olefsky JM. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism 44: 1489-1494, 1995.
10. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DF, Umesono K, and Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
11. 3 signaling. Nature 355: 446-449, 1992.
12. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774, 1992.
13. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, and Kadowaki T. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609, 1999.
14. Lee M-K, Miles PDG, Khoursheed M, Gao K-M, Moossa AR, and Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439, 1994.
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956, 1995.
16. Mangelsdorf DF, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, and Evans RM. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 66: 555-561, 1991.
17. Marks MS, Hallenbeck PL, Nagata T, Segars JH, Appella E, Nikodem VM, and Ozato K. H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinational diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J 11: 1419-1435, 1992.
18. Miles PDG, Barak Y, He W, Evans RM, and Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J Clin Invest 105: 287-292, 2000.
19. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193, 1994.
20. Okuno A, Tamemoto H, Tobe K, Ueki K, Iwamoto K, Mori Y, Umesono K, Akanuma Y, Fujimoto T, and Horikoshi H. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361, 1998.
21. Revers RR, Fink R, Griffin J, Olefsky JM, and Kolterman OG. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73: 664-672, 1984.
22. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, Staels B, and Auwerx J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15: 5336-5348, 1996.
23. Sears IB, MacGinnitie MA, Kovacs LG, and Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator activated receptor γ. Mol Cell Biol 16: 3410-3418, 1996.
24. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, and Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138: 3395-3401, 1997.
25. Steele R. Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
26. Storlien LH, James DE, Burleigh KM, Chisholm DJ, and Kraegen EW. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity. Am J Physiol Endocrinol Metab 251: E576-E583, 1986.
27. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, and Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and w-3 fatty acids in muscle phospholipid. Diabetes 40: 280-289, 1991.
28. Suter SL, Nolan JJ, Wallace P, Gumbiner B, and Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203, 1992.
29. Tontonoz P, Hu E, Graves RA, Budavari A, and Spiegelman BM. mPPARγ2: tissue specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234, 1994.
30. Tontonoz P, Hu E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
31. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, and Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998.